RBC Capital Maintains Outperform on Nuvation Bio, Lowers Price Target to $19

Benzinga Newsdesk www.benzinga.com Negative 90.2%

Neg 90.2% Neu 0% Pos 0%

RBC Capital analyst Leonid Timashev maintains Nuvation Bio (NYSE:NUVB) with a Outperform and lowers the price target from $20 to $19.